US4282201A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical comprising drug and polymer
Assignee: Alza Corp
•
Filing: 1979-11-05
•
Granted: 1981-08-04
•
Expires: 1999-11-05
Abstract
Abstract This invention concerns polymers of the general formula: ##STR1## wherein R is a multivalent hydrocarbon radical and Het is a 5 to 8 membered heterocyclic system having a nitrogen, oxygen or sulfur hetero atom. The polymers are useful for making articles of manufacture and as coating for delivering beneficial agents.
Inventors
- 👤 Nam S. Choi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 11:19
CPC Classifications
C; C08; C08G; C08G85/00; A; A01; A01N; A01N25/00; A01N25/08; A01N25/10; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204; A61L; A61L9/00; A61L9/015; A61L9/04; A61L9/042; C05; C05G; C05G5/00; C05G5/30; C05G5/37; C08G65/00; C08G65/34; C08G73/00; C08G73/06; C08G73/0605; C08G73/0611; C08G73/0622; C08G73/0627; C08L; C08L2203/00; C08L2203/02
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
401 words
A drug delivery device for the administration of drug to a biological drug receptive environment, wherein the device comprises: (I) a shaped matrix sized, structured and adapted for administering drug to the environment and formed of a drug release rate controlling pharmaceutically acceptable material, which material comprises a polymer of the formula: ##STR9## wherein R is a member selected from the group consisting of divalent, trivalent, and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkenyl of 2 to 7 carbons, an alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons, and alkylene of 2 to 10 carbons; cycloalkenylene of 4 to 7 carbons, cycloalkylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkenyl of 2 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons and alkenylene of 2 to 10 carbons; arylene of 6 to 16 carbons; arylene of 6 to 16 carbons substituted with an alkyl of 1 to 7 carbons, alkenyl of 2 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons and alkenylene of 2 to 10 carbons; and Het is a heterocyclic five to eight membered ring comprising: (1) a carbon atom bivalently bonded to the oxygen atoms of the polymer; (2) a hetero ring atom adjacent to the carbon atom of the polymer chain, said hetero atom selected from the group consisting of nitrogen, sulfur and oxygen; and (3) with the remainder of the ring independently selected from (a) and (b) wherein (a) is an alkylene bridge of 2 to 5 carbons substituted with a ring atom selected from the group consisting of nitrogen and sulfur; and (b) is an alkylene bridge of 3 to 6 carbons when said hetero atom adjacent to the carbon atom of the polymer chain is a hetero ring atom selected from the group consisting of nitrogen and sulfur; and n is greater than 10; (II) a drug selected from the group consisting of locally and systemically acting physiologically and pharmaceutically acceptable drug present in the matrix; and (III) wherein the device when in operation administers a therapeutically effective amount of drug to the environment over a period of time.
Claim 2
Dependent Claim
401 words
A drug delivery device for the administration of drug to a biological drug receptive environment, wherein the device comprises: (I) a shaped matrix sized, structured and adapted for administering drug to the environment and formed of a drug release rate controlling pharmaceutically acceptable material, which material comprises a polymer of the formula: ##STR9## wherein R is a member selected from the group consisting of divalent, trivalent, and tetravalent radicals consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene 3 to 7 carbons substituted with an alkyl of 1 to 7 carbons, an alkenyl of 2 to 7 carbons, an alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons, and alkylene of 2 to 10 carbons; cycloalkenylene of 4 to 7 carbons, cycloalkylene of 4 to 7 carbons substituted with an alkyl of 1 to 7 carbons, alkenyl of 2 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons and alkenylene of 2 to 10 carbons; arylene of 6 to 16 carbons; arylene of 6 to 16 carbons substituted with an alkyl of 1 to 7 carbons, alkenyl of 2 to 7 carbons, alkoxy of 1 to 7 carbons, alkylene of 1 to 10 carbons and alkenylene of 2 to 10 carbons; and Het is a heterocyclic five to eight membered ring comprising: (1) a carbon atom bivalently bonded to the oxygen atoms of the polymer; (2) a hetero ring atom adjacent to the carbon atom of the polymer chain, said hetero atom selected from the group consisting of nitrogen, sulfur and oxygen; and (3) with the remainder of the ring independently selected from (a) and (b) wherein (a) is an alkylene bridge of 2 to 5 carbons substituted with a ring atom selected from the group consisting of nitrogen and sulfur; and (b) is an alkylene bridge of 3 to 6 carbons when said hetero atom adjacent to the carbon atom of the polymer chain is a hetero ring atom selected from the group consisting of nitrogen and sulfur; and n is greater than 10; (II) a drug selected from the group consisting of locally and systemically acting physiologically and pharmaceutically acceptable drug present in the matrix; and (III) wherein the device when in operation administers a therapeutically effective amount of drug to the environment over a period of time.
Claim 3
Dependent Claim
21 words
The drug delivery device for the administration of drug according to claim 1 wherein the drug receptive environment is an animal.
Claim 4
Dependent Claim
33 words
The drug delivery device for the administration of drug according to claim 1 wherein the drug receptive environment is a human and the matrix contains from 0.01% to 40% by weight of drug.
Claim 5
Dependent Claim
43 words
The drug delivery device for the administration of drug according to claim 1, wherein the remainder of the heterocyclic ring comprises an alkylene bridge of 3 to 6 carbons substituted with an extralinear member selected from the group consisting of mercapto and amino.
Claim 6
Dependent Claim
59 words
The drug delivery device for the administration of drug according to claim 1, wherein the remainder of the heterocyclic ring is a dialkylene bridge of 2 to 5 carbon atoms having a linear ether between alkylene group of the bridge when the hetero atom pendant from the polymer backbone is selected from the group consisting of nitrogen and sulfur.
References Cited (Backward Citations)
US4093709A
Cited
US4131648A
Cited
US4138344A
Cited
US4180646A
Cited
US4066747A
Cited
US4119579A
Cited
US4136252A
Cited
US4155740A
Cited
US4186185A
Cited
US4070347A
Cited
US4155992A
Cited
US4122158A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-08-03 | 1985-02-02 | 1985-08-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-08-03 | 1989-02-02 | 1989-08-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-08-03 | 1993-02-02 | 1993-08-04 | $7700.00 | Window Closed / Lapsed |